Faron Pharmaceuticals Limited (AIM:FARN) CEO Dr Juho Jalkanen joined Proactive's Stephen Gunnion with details of the positive feedback from the US Food and Drug Administration (FDA) regarding its Phase III clinical trial for its lead asset, bexmarilimab (BEXMAB).
Jalkanen shared that the FDA’s guidance will accelerate trials, potentially bringing new treatments to the market sooner.
He explained, “We went with a humble attitude to the FDA, proposing a Phase III trial for relapsed refractory MDS. The big news is that the FDA recommended going directly into a frontline MDS study, opening up a much larger market sooner than anticipated.”
This acceleration not only speeds up the process but also targets a larger patient population without significantly increasing trial costs.
Jalkanen also highlighted the importance of the Frontrunner program, which promises to bring treatments to patients faster in areas of high unmet need. The feedback from the FDA will significantly impact their commercial forecasts and development plans for BEXMAB.
Faron Pharmaceuticals will continue with Phase II trials as planned, aiming to use the results for potential approval in relapsed refractory populations while preparing for Phase III trials in the frontline population next year.